Merck & Co., Inc. - Q1 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026. Merck & Co., Inc. operates in two primary segments: Pharmaceutical (human health) and Animal Health. The quarter was characterized by significant strategic acquisitions and substantial non-cash charges related to in-process research and development (IPR&D), resulting in a reported net loss despite revenue growth.
Key Financial Metrics
| Metric ($ millions) | Q1 2026 | Q1 2025 |
|---|---|---|
| Sales | 16,286 | 15,529 |
| Net (Loss) Income | (4,243) | 5,085 |
| Diluted EPS | (1.72) | 2.01 |
| Operating Cash Flow | 3,918 | 2,500 |
| Free Cash Flow (Approx. Operating - CapEx) | 2,927 | 1,172 |
| Total Debt (Current + Long-Term) | 49,117 | 49,339 |
| Cash and Investments | 6,807 | 15,521 |
| Gross Margin | 74.2% | 78.0% |
Material Changes vs. Prior Period
- Revenue Growth: Sales increased 5% year-over-year to $16.3 billion, driven by growth in oncology (Keytruda, Welireg), cardiometabolic (Winrevair), and animal health segments. This was partially offset by declines in vaccines (Gardasil) and diabetes (Januvia).
- Profitability Impact: The company reported a net loss of $4.2 billion compared to a net income of $5.1 billion in Q1 2025. This reversal was primarily due to a $9.0 billion non-cash charge for the acquisition of Cidara Therapeutics (recorded in R&D) and increased restructuring costs.
- R&D Expenses: R&D expenses surged to $12.6 billion from $3.6 billion, largely due to the Cidara acquisition charge and increased clinical development spending.
- Cash Position: Cash and cash equivalents decreased significantly from $14.6 billion to $5.3 billion due to the $8.8 billion cash outflow for the Cidara acquisition and ongoing capital expenditures.
Guidance, Outlook, and Risks
- Acquisition Outlook: Merck expects to close the acquisition of Terns Pharmaceuticals in May 2026 for approximately $6.7 billion. This is anticipated to result in a $5.8 billion charge to R&D expenses and a negative impact of approximately $0.12 per share for the remainder of 2026.
- Patent Cliffs: Key products face loss of exclusivity in 2026: Januvia/Janumet (May 2026), Janumet XR (July 2026), and Bridion (July 2026). Management anticipates a significant decline in U.S. sales for Januvia following May 2026.
- Regulatory Risks: The company is subject to the Inflation Reduction Act (IRA) drug price negotiation program. Januvia pricing was set effective January 1, 2026. Lenvima was selected for price setting effective January 1, 2028. Keytruda is expected to be selected in 2027.
- Legal Proceedings: Significant litigation includes product liability suits regarding Gardasil (a proposed settlement is under review) and Dr. Scholl's foot powder. Patent litigation regarding Keytruda (Halozyme) and Januvia (generic entry) remains active.
- Restructuring: The company is executing two restructuring programs (2024 and 2025) with estimated cumulative costs of $7.0 billion, targeting annual cost savings of $2.45 billion by 2027/2031.
Investor Verification Checklist
- Cidara Integration: Verify the timeline and clinical progress of MK-1406 (influenza prevention) to assess the return on the $9.2 billion investment.
- Terns Acquisition: Monitor the closing of the Terns deal and the specific clinical data for TERN-701 (CML treatment) to validate the $6.7 billion valuation.
- Januvia Sales Trajectory: Track monthly sales data post-May 2026 to quantify the impact of generic entry and IRA price negotiations.
- Keytruda Patent Litigation: Review updates on the Halozyme litigation regarding subcutaneous pembrolizumab, which could impact sales in Germany and other markets.
- Cash Flow Sustainability: Assess the company's ability to fund the Terns acquisition and ongoing R&D while maintaining dividend payments and share repurchases given the reduced cash balance.